BTAI - Company ID 0001720893
The table below shows BioXcel Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $206.00K | $98.00K | $120.00K | $168.00K | $214.00K | $1.10M |
| Cost of revenue | $283.00K | $11.00K | $107.00K | $14.00K | $1.17M | $62.00K |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.96M | $8.74M | $10.26M | $4.55M | $5.10M | $8.03M |
BioXcel Therapeutics, Inc. reported annual revenue of $642.00K for fiscal year 2025. That is down 71.7% from $2.27M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $7.19M |
| $5.38M |
| $5.61M |
| $5.70M |
| $7.68M |
| $9.45M |
| Operating income | -$10.22M | -$14.23M | -$15.85M | -$10.10M | -$15.29M | -$17.30M |
| Income tax | - | - | - | - | - | - |
| Net income | -$12.69M | -$30.91M | -$19.19M | -$7.25M | -$13.65M | -$8.30M |
| EPS (diluted) | -$0.54 | -$2.18 | -$2.45 | -$1.50 | -$5.15 | -$3.30 |